STOP-CoV study results highlights importance of completing primary vaccine series

In a pre-print, not yet peer reviewed, the team from the STOP-CoV study, led by Dr. Sharon Walmsley from the University Health Network in Toronto, described their most recent findings: younger adults (30-50) generate higher levels of vaccine-specific antibodies compared to older adults (70 and above) after both the first and second mRNA vaccine doses.